English
简体中文
Total: £ 56.28
Published Date: 2025-04-08 | Pages: 105 | Tables: 102 | Pharma & Healthcare
The global market for Second-Generation Antipsychotics was valued at US$ 45000 million in the year 2024 and is projected to reach a revised size of US$ 50570 million by 2031, growing at a CAGR of 1.7% during the forecast period.
Second-generation antipsychotics, also known as atypical antipsychotics or novel antipsychotics. Compared with the first generation drugs, the second generation antipsychotic drugs have significant differences in pharmacological mechanisms, clinical efficacy, and side effect profiles, making them the mainstream choice for the treatment of severe mental disorders such as schizophrenia and bipolar disorder. From the perspective of pharmacological mechanisms, second-generation antipsychotics can be divided into four categories: 5-hydroxytryptamine and dopamine receptor antagonists (such as risperidone, olanzapine, quetiapine, and ziprasidone), multi receptor acting drugs (such as clozapine), selective dopamine receptor antagonists (such as amisulpride), and dopamine receptor partial agonists (such as aripiprazole).
The global market for second-generation antipsychotics has shown a growth trend in recent years. Core products such as olanzapine, quetiapine, and risperidone have long dominated sales, while relatively new drugs such as aripiprazole and ziprasidone have also shown good growth momentum. The main driving factors of the market include the increasing burden of mental illness, changes in treatment concepts, increased policy support, and breakthroughs in research and development innovation. The market has significant regional differences. Currently, North America holds the largest market share, with multinational pharmaceutical giants such as Pfizer, Eli Lilly, Novartis, and Merck dominating the market. The European market follows closely behind, with a slightly slower growth rate than North America, but the competitive landscape is more fragmented with numerous participants. In the Asia Pacific region, the Japanese market is relatively small and growing slowly, dominated by several large local pharmaceutical companies. The Chinese and Indian markets are not large in scale, but their growth rates are significantly higher than the global average, making them key regions for global pharmaceutical companies to layout. In the future, market differentiation will intensify, and original drugs with expired patents will face fierce competition from generic drugs, resulting in a significant decrease in prices, while new mechanism drugs with significant clinical advantages can gain premium space. Early intervention for mental illness will receive more attention, and the demand for low-dose formulations and drugs with fewer side effects suitable for early intervention will increase. Digital health technologies such as electronic prescriptions, telemedicine, and medication compliance monitoring will be deeply integrated with antipsychotic drug treatment. Emerging economies such as China and India will become important engines of global growth. With the improvement of medical infrastructure and increased payment capacity, the demand for high-quality antipsychotic drugs will rapidly grow, providing strategic opportunities for global pharmaceutical companies.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Second-Generation Antipsychotics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Second-Generation Antipsychotics.
The Second-Generation Antipsychotics market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Second-Generation Antipsychotics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Second-Generation Antipsychotics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Sumitomo Dainippon Pharma
Roche
Pfizer
Novartis
Otsuka Pharmaceutical
AbbVie
Johnson And Johnson
Ipsen
Merck
Eli Lilly
Luye Pharma Group
Nhwa Pharmaceutical
Livzon Pharmaceutical Group
Qilu Pharmaceutical
CSPC Pharmaceutical Group
Chengdu Kanghong Pharmaceutical
Hansoh Pharma
Hisun Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Yangtze River Pharmaceutical Group
Segment by Type
5-Hydroxytryptamine And Dopamine Receptor Antagonists
Multi Receptor Acting Drugs
Selective Dopamine Receptor Antagonists
Dopamine Receptor Partial Agonists
Segment by Application
Schizophrenia
Bipolar Disorder
Adjuvant Treatment For Depression
Other Mental Illnesses
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Second-Generation Antipsychotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Second-Generation Antipsychotics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Second-Generation Antipsychotics Market Overview
1.1 Product Definition
1.2 Second-Generation Antipsychotics by Type
1.2.1 Global Second-Generation Antipsychotics Market Value Comparison by Type (2024 VS 2031)
1.2.2 5-Hydroxytryptamine And Dopamine Receptor Antagonists
1.2.3 Multi Receptor Acting Drugs
1.2.4 Selective Dopamine Receptor Antagonists
1.2.5 Dopamine Receptor Partial Agonists
1.3 Second-Generation Antipsychotics by Application
1.3.1 Global Second-Generation Antipsychotics Market Value by Application (2024 VS 2031)
1.3.2 Schizophrenia
1.3.3 Bipolar Disorder
1.3.4 Adjuvant Treatment For Depression
1.3.5 Other Mental Illnesses
1.4 Global Second-Generation Antipsychotics Market Size Estimates and Forecasts
1.4.1 Global Second-Generation Antipsychotics Revenue 2020-2031
1.4.2 Global Second-Generation Antipsychotics Sales 2020-2031
1.4.3 Global Second-Generation Antipsychotics Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Second-Generation Antipsychotics Market Competition by Manufacturers
2.1 Global Second-Generation Antipsychotics Sales Market Share by Manufacturers (2020-2025)
2.2 Global Second-Generation Antipsychotics Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Second-Generation Antipsychotics Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Second-Generation Antipsychotics, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Second-Generation Antipsychotics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Second-Generation Antipsychotics, Product Type & Application
2.7 Global Key Manufacturers of Second-Generation Antipsychotics, Date of Enter into This Industry
2.8 Global Second-Generation Antipsychotics Market Competitive Situation and Trends
2.8.1 Global Second-Generation Antipsychotics Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Second-Generation Antipsychotics Players Market Share by Revenue
2.8.3 Global Second-Generation Antipsychotics Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Second-Generation Antipsychotics Market Scenario by Region
3.1 Global Second-Generation Antipsychotics Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Second-Generation Antipsychotics Sales by Region: 2020-2031
3.2.1 Global Second-Generation Antipsychotics Sales by Region: 2020-2025
3.2.2 Global Second-Generation Antipsychotics Sales by Region: 2026-2031
3.3 Global Second-Generation Antipsychotics Revenue by Region: 2020-2031
3.3.1 Global Second-Generation Antipsychotics Revenue by Region: 2020-2025
3.3.2 Global Second-Generation Antipsychotics Revenue by Region: 2026-2031
3.4 North America Second-Generation Antipsychotics Market Facts & Figures by Country
3.4.1 North America Second-Generation Antipsychotics Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Second-Generation Antipsychotics Sales by Country (2020-2031)
3.4.3 North America Second-Generation Antipsychotics Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Second-Generation Antipsychotics Market Facts & Figures by Country
3.5.1 Europe Second-Generation Antipsychotics Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Second-Generation Antipsychotics Sales by Country (2020-2031)
3.5.3 Europe Second-Generation Antipsychotics Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Second-Generation Antipsychotics Market Facts & Figures by Region
3.6.1 Asia Pacific Second-Generation Antipsychotics Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Second-Generation Antipsychotics Sales by Region (2020-2031)
3.6.3 Asia Pacific Second-Generation Antipsychotics Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Second-Generation Antipsychotics Market Facts & Figures by Country
3.7.1 Latin America Second-Generation Antipsychotics Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Second-Generation Antipsychotics Sales by Country (2020-2031)
3.7.3 Latin America Second-Generation Antipsychotics Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Second-Generation Antipsychotics Market Facts & Figures by Country
3.8.1 Middle East and Africa Second-Generation Antipsychotics Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Second-Generation Antipsychotics Sales by Country (2020-2031)
3.8.3 Middle East and Africa Second-Generation Antipsychotics Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Second-Generation Antipsychotics Sales by Type (2020-2031)
4.1.1 Global Second-Generation Antipsychotics Sales by Type (2020-2025)
4.1.2 Global Second-Generation Antipsychotics Sales by Type (2026-2031)
4.1.3 Global Second-Generation Antipsychotics Sales Market Share by Type (2020-2031)
4.2 Global Second-Generation Antipsychotics Revenue by Type (2020-2031)
4.2.1 Global Second-Generation Antipsychotics Revenue by Type (2020-2025)
4.2.2 Global Second-Generation Antipsychotics Revenue by Type (2026-2031)
4.2.3 Global Second-Generation Antipsychotics Revenue Market Share by Type (2020-2031)
4.3 Global Second-Generation Antipsychotics Price by Type (2020-2031)
5 Segment by Application
5.1 Global Second-Generation Antipsychotics Sales by Application (2020-2031)
5.1.1 Global Second-Generation Antipsychotics Sales by Application (2020-2025)
5.1.2 Global Second-Generation Antipsychotics Sales by Application (2026-2031)
5.1.3 Global Second-Generation Antipsychotics Sales Market Share by Application (2020-2031)
5.2 Global Second-Generation Antipsychotics Revenue by Application (2020-2031)
5.2.1 Global Second-Generation Antipsychotics Revenue by Application (2020-2025)
5.2.2 Global Second-Generation Antipsychotics Revenue by Application (2026-2031)
5.2.3 Global Second-Generation Antipsychotics Revenue Market Share by Application (2020-2031)
5.3 Global Second-Generation Antipsychotics Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sumitomo Dainippon Pharma
6.1.1 Sumitomo Dainippon Pharma Company Information
6.1.2 Sumitomo Dainippon Pharma Description and Business Overview
6.1.3 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product Portfolio
6.1.5 Sumitomo Dainippon Pharma Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche Second-Generation Antipsychotics Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Second-Generation Antipsychotics Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Second-Generation Antipsychotics Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Otsuka Pharmaceutical
6.5.1 Otsuka Pharmaceutical Company Information
6.5.2 Otsuka Pharmaceutical Description and Business Overview
6.5.3 Otsuka Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Otsuka Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.5.5 Otsuka Pharmaceutical Recent Developments/Updates
6.6 AbbVie
6.6.1 AbbVie Company Information
6.6.2 AbbVie Description and Business Overview
6.6.3 AbbVie Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.6.4 AbbVie Second-Generation Antipsychotics Product Portfolio
6.6.5 AbbVie Recent Developments/Updates
6.7 Johnson And Johnson
6.7.1 Johnson And Johnson Company Information
6.7.2 Johnson And Johnson Description and Business Overview
6.7.3 Johnson And Johnson Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Johnson And Johnson Second-Generation Antipsychotics Product Portfolio
6.7.5 Johnson And Johnson Recent Developments/Updates
6.8 Ipsen
6.8.1 Ipsen Company Information
6.8.2 Ipsen Description and Business Overview
6.8.3 Ipsen Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Ipsen Second-Generation Antipsychotics Product Portfolio
6.8.5 Ipsen Recent Developments/Updates
6.9 Merck
6.9.1 Merck Company Information
6.9.2 Merck Description and Business Overview
6.9.3 Merck Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Merck Second-Generation Antipsychotics Product Portfolio
6.9.5 Merck Recent Developments/Updates
6.10 Eli Lilly
6.10.1 Eli Lilly Company Information
6.10.2 Eli Lilly Description and Business Overview
6.10.3 Eli Lilly Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Eli Lilly Second-Generation Antipsychotics Product Portfolio
6.10.5 Eli Lilly Recent Developments/Updates
6.11 Luye Pharma Group
6.11.1 Luye Pharma Group Company Information
6.11.2 Luye Pharma Group Description and Business Overview
6.11.3 Luye Pharma Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Luye Pharma Group Second-Generation Antipsychotics Product Portfolio
6.11.5 Luye Pharma Group Recent Developments/Updates
6.12 Nhwa Pharmaceutical
6.12.1 Nhwa Pharmaceutical Company Information
6.12.2 Nhwa Pharmaceutical Description and Business Overview
6.12.3 Nhwa Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Nhwa Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.12.5 Nhwa Pharmaceutical Recent Developments/Updates
6.13 Livzon Pharmaceutical Group
6.13.1 Livzon Pharmaceutical Group Company Information
6.13.2 Livzon Pharmaceutical Group Description and Business Overview
6.13.3 Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Livzon Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
6.13.5 Livzon Pharmaceutical Group Recent Developments/Updates
6.14 Qilu Pharmaceutical
6.14.1 Qilu Pharmaceutical Company Information
6.14.2 Qilu Pharmaceutical Description and Business Overview
6.14.3 Qilu Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Qilu Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.14.5 Qilu Pharmaceutical Recent Developments/Updates
6.15 CSPC Pharmaceutical Group
6.15.1 CSPC Pharmaceutical Group Company Information
6.15.2 CSPC Pharmaceutical Group Description and Business Overview
6.15.3 CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.15.4 CSPC Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
6.15.5 CSPC Pharmaceutical Group Recent Developments/Updates
6.16 Chengdu Kanghong Pharmaceutical
6.16.1 Chengdu Kanghong Pharmaceutical Company Information
6.16.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.16.3 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.16.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
6.17 Hansoh Pharma
6.17.1 Hansoh Pharma Company Information
6.17.2 Hansoh Pharma Description and Business Overview
6.17.3 Hansoh Pharma Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Hansoh Pharma Second-Generation Antipsychotics Product Portfolio
6.17.5 Hansoh Pharma Recent Developments/Updates
6.18 Hisun Pharmaceutical
6.18.1 Hisun Pharmaceutical Company Information
6.18.2 Hisun Pharmaceutical Description and Business Overview
6.18.3 Hisun Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Hisun Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.18.5 Hisun Pharmaceutical Recent Developments/Updates
6.19 Chia Tai Tianqing Pharmaceutical
6.19.1 Chia Tai Tianqing Pharmaceutical Company Information
6.19.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.19.3 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product Portfolio
6.19.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
6.20 Yangtze River Pharmaceutical Group
6.20.1 Yangtze River Pharmaceutical Group Company Information
6.20.2 Yangtze River Pharmaceutical Group Description and Business Overview
6.20.3 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
6.20.5 Yangtze River Pharmaceutical Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Second-Generation Antipsychotics Industry Chain Analysis
7.2 Second-Generation Antipsychotics Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Second-Generation Antipsychotics Production Mode & Process Analysis
7.4 Second-Generation Antipsychotics Sales and Marketing
7.4.1 Second-Generation Antipsychotics Sales Channels
7.4.2 Second-Generation Antipsychotics Distributors
7.5 Second-Generation Antipsychotics Customer Analysis
8 Second-Generation Antipsychotics Market Dynamics
8.1 Second-Generation Antipsychotics Industry Trends
8.2 Second-Generation Antipsychotics Market Drivers
8.3 Second-Generation Antipsychotics Market Challenges
8.4 Second-Generation Antipsychotics Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Second-Generation Antipsychotics Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Second-Generation Antipsychotics Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Second-Generation Antipsychotics Market Competitive Situation by Manufacturers in 2024
Table 4. Global Second-Generation Antipsychotics Sales (Units) of Key Manufacturers (2020-2025)
Table 5. Global Second-Generation Antipsychotics Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Second-Generation Antipsychotics Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Second-Generation Antipsychotics Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Second-Generation Antipsychotics Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Second-Generation Antipsychotics, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Second-Generation Antipsychotics, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Second-Generation Antipsychotics, Product Type & Application
Table 12. Global Key Manufacturers of Second-Generation Antipsychotics, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Second-Generation Antipsychotics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Second-Generation Antipsychotics as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Second-Generation Antipsychotics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Second-Generation Antipsychotics Sales by Region (2020-2025) & (Units)
Table 18. Global Second-Generation Antipsychotics Sales Market Share by Region (2020-2025)
Table 19. Global Second-Generation Antipsychotics Sales by Region (2026-2031) & (Units)
Table 20. Global Second-Generation Antipsychotics Sales Market Share by Region (2026-2031)
Table 21. Global Second-Generation Antipsychotics Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Second-Generation Antipsychotics Revenue Market Share by Region (2020-2025)
Table 23. Global Second-Generation Antipsychotics Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Second-Generation Antipsychotics Revenue Market Share by Region (2026-2031)
Table 25. North America Second-Generation Antipsychotics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Second-Generation Antipsychotics Sales by Country (2020-2025) & (Units)
Table 27. North America Second-Generation Antipsychotics Sales by Country (2026-2031) & (Units)
Table 28. North America Second-Generation Antipsychotics Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Second-Generation Antipsychotics Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Second-Generation Antipsychotics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Second-Generation Antipsychotics Sales by Country (2020-2025) & (Units)
Table 32. Europe Second-Generation Antipsychotics Sales by Country (2026-2031) & (Units)
Table 33. Europe Second-Generation Antipsychotics Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Second-Generation Antipsychotics Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Second-Generation Antipsychotics Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Second-Generation Antipsychotics Sales by Region (2020-2025) & (Units)
Table 37. Asia Pacific Second-Generation Antipsychotics Sales by Region (2026-2031) & (Units)
Table 38. Asia Pacific Second-Generation Antipsychotics Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Second-Generation Antipsychotics Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Second-Generation Antipsychotics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Second-Generation Antipsychotics Sales by Country (2020-2025) & (Units)
Table 42. Latin America Second-Generation Antipsychotics Sales by Country (2026-2031) & (Units)
Table 43. Latin America Second-Generation Antipsychotics Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Second-Generation Antipsychotics Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Second-Generation Antipsychotics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Second-Generation Antipsychotics Sales by Country (2020-2025) & (Units)
Table 47. Middle East and Africa Second-Generation Antipsychotics Sales by Country (2026-2031) & (Units)
Table 48. Middle East and Africa Second-Generation Antipsychotics Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Second-Generation Antipsychotics Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Second-Generation Antipsychotics Sales (Units) by Type (2020-2025)
Table 51. Global Second-Generation Antipsychotics Sales (Units) by Type (2026-2031)
Table 52. Global Second-Generation Antipsychotics Sales Market Share by Type (2020-2025)
Table 53. Global Second-Generation Antipsychotics Sales Market Share by Type (2026-2031)
Table 54. Global Second-Generation Antipsychotics Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Second-Generation Antipsychotics Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Second-Generation Antipsychotics Revenue Market Share by Type (2020-2025)
Table 57. Global Second-Generation Antipsychotics Revenue Market Share by Type (2026-2031)
Table 58. Global Second-Generation Antipsychotics Price (US$/Unit) by Type (2020-2025)
Table 59. Global Second-Generation Antipsychotics Price (US$/Unit) by Type (2026-2031)
Table 60. Global Second-Generation Antipsychotics Sales (Units) by Application (2020-2025)
Table 61. Global Second-Generation Antipsychotics Sales (Units) by Application (2026-2031)
Table 62. Global Second-Generation Antipsychotics Sales Market Share by Application (2020-2025)
Table 63. Global Second-Generation Antipsychotics Sales Market Share by Application (2026-2031)
Table 64. Global Second-Generation Antipsychotics Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Second-Generation Antipsychotics Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Second-Generation Antipsychotics Revenue Market Share by Application (2020-2025)
Table 67. Global Second-Generation Antipsychotics Revenue Market Share by Application (2026-2031)
Table 68. Global Second-Generation Antipsychotics Price (US$/Unit) by Application (2020-2025)
Table 69. Global Second-Generation Antipsychotics Price (US$/Unit) by Application (2026-2031)
Table 70. Sumitomo Dainippon Pharma Company Information
Table 71. Sumitomo Dainippon Pharma Description and Business Overview
Table 72. Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product
Table 74. Sumitomo Dainippon Pharma Recent Developments/Updates
Table 75. Roche Company Information
Table 76. Roche Description and Business Overview
Table 77. Roche Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Roche Second-Generation Antipsychotics Product
Table 79. Roche Recent Developments/Updates
Table 80. Pfizer Company Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Pfizer Second-Generation Antipsychotics Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Novartis Company Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Novartis Second-Generation Antipsychotics Product
Table 89. Novartis Recent Developments/Updates
Table 90. Otsuka Pharmaceutical Company Information
Table 91. Otsuka Pharmaceutical Description and Business Overview
Table 92. Otsuka Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Otsuka Pharmaceutical Second-Generation Antipsychotics Product
Table 94. Otsuka Pharmaceutical Recent Developments/Updates
Table 95. AbbVie Company Information
Table 96. AbbVie Description and Business Overview
Table 97. AbbVie Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. AbbVie Second-Generation Antipsychotics Product
Table 99. AbbVie Recent Developments/Updates
Table 100. Johnson And Johnson Company Information
Table 101. Johnson And Johnson Description and Business Overview
Table 102. Johnson And Johnson Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Johnson And Johnson Second-Generation Antipsychotics Product
Table 104. Johnson And Johnson Recent Developments/Updates
Table 105. Ipsen Company Information
Table 106. Ipsen Description and Business Overview
Table 107. Ipsen Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Ipsen Second-Generation Antipsychotics Product
Table 109. Ipsen Recent Developments/Updates
Table 110. Merck Company Information
Table 111. Merck Description and Business Overview
Table 112. Merck Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Merck Second-Generation Antipsychotics Product
Table 114. Merck Recent Developments/Updates
Table 115. Eli Lilly Company Information
Table 116. Eli Lilly Description and Business Overview
Table 117. Eli Lilly Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Eli Lilly Second-Generation Antipsychotics Product
Table 119. Eli Lilly Recent Developments/Updates
Table 120. Luye Pharma Group Company Information
Table 121. Luye Pharma Group Description and Business Overview
Table 122. Luye Pharma Group Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Luye Pharma Group Second-Generation Antipsychotics Product
Table 124. Luye Pharma Group Recent Developments/Updates
Table 125. Nhwa Pharmaceutical Company Information
Table 126. Nhwa Pharmaceutical Description and Business Overview
Table 127. Nhwa Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Nhwa Pharmaceutical Second-Generation Antipsychotics Product
Table 129. Nhwa Pharmaceutical Recent Developments/Updates
Table 130. Livzon Pharmaceutical Group Company Information
Table 131. Livzon Pharmaceutical Group Description and Business Overview
Table 132. Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Livzon Pharmaceutical Group Second-Generation Antipsychotics Product
Table 134. Livzon Pharmaceutical Group Recent Developments/Updates
Table 135. Qilu Pharmaceutical Company Information
Table 136. Qilu Pharmaceutical Description and Business Overview
Table 137. Qilu Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Qilu Pharmaceutical Second-Generation Antipsychotics Product
Table 139. Qilu Pharmaceutical Recent Developments/Updates
Table 140. CSPC Pharmaceutical Group Company Information
Table 141. CSPC Pharmaceutical Group Description and Business Overview
Table 142. CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. CSPC Pharmaceutical Group Second-Generation Antipsychotics Product
Table 144. CSPC Pharmaceutical Group Recent Developments/Updates
Table 145. Chengdu Kanghong Pharmaceutical Company Information
Table 146. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 147. Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product
Table 149. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 150. Hansoh Pharma Company Information
Table 151. Hansoh Pharma Description and Business Overview
Table 152. Hansoh Pharma Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Hansoh Pharma Second-Generation Antipsychotics Product
Table 154. Hansoh Pharma Recent Developments/Updates
Table 155. Hisun Pharmaceutical Company Information
Table 156. Hisun Pharmaceutical Description and Business Overview
Table 157. Hisun Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 158. Hisun Pharmaceutical Second-Generation Antipsychotics Product
Table 159. Hisun Pharmaceutical Recent Developments/Updates
Table 160. Chia Tai Tianqing Pharmaceutical Company Information
Table 161. Chia Tai Tianqing Pharmaceutical Description and Business Overview
Table 162. Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 163. Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product
Table 164. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
Table 165. Yangtze River Pharmaceutical Group Company Information
Table 166. Yangtze River Pharmaceutical Group Description and Business Overview
Table 167. Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 168. Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product
Table 169. Yangtze River Pharmaceutical Group Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Second-Generation Antipsychotics Distributors List
Table 173. Second-Generation Antipsychotics Customers List
Table 174. Second-Generation Antipsychotics Market Trends
Table 175. Second-Generation Antipsychotics Market Drivers
Table 176. Second-Generation Antipsychotics Market Challenges
Table 177. Second-Generation Antipsychotics Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
Table 181. Authors List of This Report
List of Figures
Figure 1. Product Picture of Second-Generation Antipsychotics
Figure 2. Global Second-Generation Antipsychotics Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Second-Generation Antipsychotics Market Share by Type: 2024 & 2031
Figure 4. 5-Hydroxytryptamine And Dopamine Receptor Antagonists Product Picture
Figure 5. Multi Receptor Acting Drugs Product Picture
Figure 6. Selective Dopamine Receptor Antagonists Product Picture
Figure 7. Dopamine Receptor Partial Agonists Product Picture
Figure 8. Global Second-Generation Antipsychotics Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Second-Generation Antipsychotics Market Share by Application: 2024 & 2031
Figure 10. Schizophrenia
Figure 11. Bipolar Disorder
Figure 12. Adjuvant Treatment For Depression
Figure 13. Other Mental Illnesses
Figure 14. Global Second-Generation Antipsychotics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Second-Generation Antipsychotics Market Size (2020-2031) & (US$ Million)
Figure 16. Global Second-Generation Antipsychotics Sales (2020-2031) & (Units)
Figure 17. Global Second-Generation Antipsychotics Average Price (US$/Unit) & (2020-2031)
Figure 18. Second-Generation Antipsychotics Report Years Considered
Figure 19. Second-Generation Antipsychotics Sales Share by Manufacturers in 2024
Figure 20. Global Second-Generation Antipsychotics Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Second-Generation Antipsychotics Players: Market Share by Revenue in Second-Generation Antipsychotics in 2024
Figure 22. Second-Generation Antipsychotics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Second-Generation Antipsychotics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Second-Generation Antipsychotics Sales Market Share by Country (2020-2031)
Figure 25. North America Second-Generation Antipsychotics Revenue Market Share by Country (2020-2031)
Figure 26. United States Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Second-Generation Antipsychotics Sales Market Share by Country (2020-2031)
Figure 29. Europe Second-Generation Antipsychotics Revenue Market Share by Country (2020-2031)
Figure 30. Germany Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Second-Generation Antipsychotics Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Second-Generation Antipsychotics Revenue Market Share by Region (2020-2031)
Figure 37. China Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. China Taiwan Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Southeast Asia Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Second-Generation Antipsychotics Sales Market Share by Country (2020-2031)
Figure 45. Latin America Second-Generation Antipsychotics Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Colombia Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Second-Generation Antipsychotics Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Second-Generation Antipsychotics Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. UAE Second-Generation Antipsychotics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Second-Generation Antipsychotics by Type (2020-2031)
Figure 56. Global Revenue Market Share of Second-Generation Antipsychotics by Type (2020-2031)
Figure 57. Global Second-Generation Antipsychotics Price (US$/Unit) by Type (2020-2031)
Figure 58. Global Sales Market Share of Second-Generation Antipsychotics by Application (2020-2031)
Figure 59. Global Revenue Market Share of Second-Generation Antipsychotics by Application (2020-2031)
Figure 60. Global Second-Generation Antipsychotics Price (US$/Unit) by Application (2020-2031)
Figure 61. Second-Generation Antipsychotics Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
